{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:08:35Z","timestamp":1765004915624,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Nilotinib is used as standard treatment in managing chronic myeloid leukaemia (CML). A 23-year-old man with CML and on nilotinib was admitted to the intensive care unit due to respiratory failure. Three years prior, he developed pleural effusion from dasatinib therapy thus, his CML regimen was changed to nilotinib. Although the pleural effusion had once improved, the chest imaging revealed left-dominant bilateral pleural effusion. Endotracheal intubation and left thoracic drainage were performed. Nilotinib treatment was discontinued, and approximately 60\u2009hours later, nilotinib concentrations of 927 and 2092\u2009ng\/mL were determined in his blood and pleural effusion, respectively. Severe pleural effusion may be induced in patients administering nilotinib, and nilotinib concentrations in blood and pleural effusion can be elevated in patients with nilotinib-related pleural effusion. Cross-occurrence of pleural effusions needs to be monitored precisely, especially in patients who are switched to other tyrosine kinase inhibitors after dasatinib treatment.<\/jats:p>","DOI":"10.1136\/bcr-2021-243671","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T12:07:40Z","timestamp":1630670860000},"page":"e243671","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2182-3108","authenticated-orcid":false,"given":"Kasumi","family":"Satoh","sequence":"first","affiliation":[{"name":"Advanced Emergency and Critical Care Center, Akita University Hospital, Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Morisawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital, Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Advanced Emergency and Critical Care Center, Akita University Hospital, Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Nakae","sequence":"additional","affiliation":[{"name":"Advanced Emergency and Critical Care Center, Akita University Hospital, Akita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2025082804375903000_14.9.e243671.1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: a literature review","volume":"12","author":"Sampaio","year":"2021","journal-title":"World J Clin Oncol"},{"key":"2025082804375903000_14.9.e243671.2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-46"},{"key":"2025082804375903000_14.9.e243671.3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jjcc.2019.07.008","article-title":"The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia","volume":"75","author":"Aoyama","year":"2020","journal-title":"J Cardiol"},{"key":"2025082804375903000_14.9.e243671.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"2025082804375903000_14.9.e243671.5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2025082804375903000_14.9.e243671.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.08.002"},{"key":"2025082804375903000_14.9.e243671.7","unstructured":"Highlights of prescribing information, FDA. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022068s029lbl.pdf [Accessed 17 Mar 2021]."},{"key":"2025082804375903000_14.9.e243671.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR"},{"key":"2025082804375903000_14.9.e243671.9","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212447530"},{"key":"2025082804375903000_14.9.e243671.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/203939","article-title":"Pleural effusion: a rare side effect of nilotinib-a case report","volume":"2014","author":"Usk\u00fcdar Teke","year":"2014","journal-title":"Case Rep Med"},{"key":"2025082804375903000_14.9.e243671.11","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181ae9227"},{"key":"2025082804375903000_14.9.e243671.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01410-2016"},{"key":"2025082804375903000_14.9.e243671.13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2025082804375903000_14.9.e243671.14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2025082804375903000_14.9.e243671.15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-013-0562-5","article-title":"Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia","volume":"19","author":"Shibata","year":"2014","journal-title":"Int J Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:38:09Z","timestamp":1756381089000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2021-243671"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243671","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}